Table 1 Demographic and Clinical Characteristics at the Time of Diagnosis
From: Bronchiectasis diagnosed after renal transplantation: a retrospective multicenter study
Variables | Total (n = 46) |
|---|---|
Male | 24 (52.2) |
Age (years) | 58.2 ± 13.6 [20.4–82.1] |
Duration of symptoms before diagnosis (years) | 1.5 ± 2.3 [0–12.1] |
Presenting symptoms | |
Cough and sputum > 3 months | 23 (50.0) |
Hemoptysis | 2 (4.3) |
Single respiratory tract infection | 14 (30.4) |
Recurrent bronchitis | 16 (34.8) |
Recurrent pneumonia | 9 (19.6) |
Incidental | 3 (6.5) |
Interval between first renal transplantation and first symptoms (years) | 9.1 ± 7.3 (0.2–25.3) |
Interval between first renal transplantation and diagnosis (years) | 10.9 ± 7.5 (0.4–32.0) |
Cause of end-stage renal disease | |
Chronic glomerulonephritis | 10 (21.7) |
Diabetic nephropathy | 0 (0) |
Autosomal dominant polycystic kidney disease | 15 (32.6) |
Chronic tubulointerstitial nephritis | 11 (23.9) |
Unknown cause of end-stage renal disease | 4 (8.7) |
Other renal disease | 6 (13.0) |
Age at the first renal transplantation (years) | 47.3 ± 15.1 [9.4–72.9] |
Number of renal transplantations | |
One renal transplantation | 41 (89.1) |
Two renal transplantations | 4 (8.7) |
Three renal transplantations | 1 (2.2) |
Immunosuppressive regimen | |
Induction therapy | |
Anti-lymphocyte globulins | 21 (45.7) |
Basiliximab | 8 (17.4) |
Steroids | 46 (100) |
Purine synthesis inhibitor | |
Mycophenolic acid (MPA) | 43 (93.5) |
Azathioprine | 14 (30.4) |
Calcineurin inhibitors | |
Cyclosporine | 32 (69.6) |
Tacrolimus | 15 (32.5) |
mTOR inhibitors | |
Sirolimus | 12 (26.1) |
Everolimus | 1 (2.2) |
Rituximab | 1 (2.2) |